NCT00358228View on ClinicalTrials.gov

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)

PHASE3CompletedINTERVENTIONAL
Enrollment

787

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

August 31, 2003

Study Completion Date

August 31, 2003

Conditions
Smoking Cessation
Interventions
DRUG

Rimonabant

Trial Locations (1)

19355

Sanofi-Aventis Administrative Office, Malvern

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00358228 - Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US) | Biotech Hunter | Biotech Hunter